CORT Q3 2023 Earnings — Corcept Therapeutics Incorporated Revenue & Financial Results | Market Cap Arena

CORTCorcept Therapeutics Incorporated

$4B

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$124M+21.5% YoY

Gross Profit

$122M98.7% margin

Operating Income

$31M25.2% margin

Net Income

$31M25.4% margin

EPS (Diluted)

$0.28

QoQ Revenue Growth

+5.0%

Cash Flow

Operating Cash Flow

$53M

Free Cash Flow

$53M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$594M

Total Liabilities

$132M

Stockholders' Equity

$462M

Cash & Equivalents

$112M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$124M	$102M	+21.5%
Gross Profit	$122M	$100M	+21.5%
Operating Income	$31M	$32M	-2.4%
Net Income	$31M	$35M	-9.3%